A state-of-the-art driving simulator allows you to conduct FDA-required testing in complete safety.
The Food and Drug Administration (FDA) recently stated that, beginning with first-in-human studies, all drugs, including drugs intended for non-CNS indications, should be evaluated for adverse effects on the central nervous system (CNS) e.g. somnolence, agitation, dizziness. The draft guidance indicates that the occurrence of adverse CNS events in even a small number of Phase I subjects can attest to the need for more focused studies of CNS effects, including dedicated driving studies.
Algorithme Pharma and Cognitive Research Corporation (CRC) have extensive experience in the design and execution of driving simulation studies to help you evaluate the effects of drugs on the ability to operate a motor vehicle... without risk of injury.